UTHR Stock News & Catalysts – United Therapeutics

FEATURED

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

New

United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update during fireside chat sessions at two upcoming investor

Summary

Nov 9, 2026, 7:00 AM ·Business Wire

RECENT

United Therapeutics Announces Buydown of Ralinepag Royalty

The transaction eliminates the double-digit royalty payable to Pfizer on net sales of ralinepag Royalty elimination applies to all formulations of ralinepag, including both oral and inhaled United Therapeutics

Nov 4, 2026, 7:00 AM ·Business Wire

United Therapeutics Corporation Reports Third Quarter 2026 Financial Results

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2026. Total revenues in the third quarter of 2026 increased by

Nov 4, 2026, 6:30 AM ·Business Wire

United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension

If successful, Treprostinil-Iloprost SMI would be the first use-as-needed combination inhaled therapy to be developed for pulmonary arterial hypertension (PAH) This investigational therapy combines two potent

Oct 28, 2026, 7:00 AM ·Business Wire

United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors has authorized a new share repurchase program for up to $2 billion of the company’s

Oct 22, 2026, 7:00 AM ·Business Wire

United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release that will be issued on Wednesday, November 4, 2026, at approximately 6:30

Oct 21, 2026, 7:00 AM ·Business Wire

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

Named for Dr. Bartley P. Griffith and Dr. Robert A. Montgomery, pioneers in xenotransplantation, the biosecure facility is purpose-built to manufacture United Therapeutics’ xenokidneys and xenohearts for its rapidly

Oct 20, 2026, 7:00 AM ·Business Wire

United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD

The development of a soft mist inhaler (SMI) represents a further advancement of treprostinil delivery devices to potentially address a wider range of patient tolerability profiles A soft mist formulation may be

Oct 19, 2026, 7:00 AM ·Business Wire

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

Fully resolves all six ongoing lawsuits between the companiesMaintains uninterrupted access to YUTREPIA® for patients with pulmonary arterial hypertension (PAH)Liquidia to pay net $380.7 million in multiple installments

Oct 13, 2026, 5:44 PM ·Globe Newswire

United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting

A pre-specified subgroup analysis from the phase 3 ADVANCE OUTCOMES study showed that ralinepag reduced the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH), regardless of how many

Oct 13, 2026, 7:00 AM ·Business Wire

HLS Therapeutics Announces Board of Directors Changes

TORONTO, Oct. 1, 2026 /CNW/ -- HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Directors

Oct 1, 2026, 7:00 AM ·PRNewswire

United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc.

Sep 30, 2026, 7:09 PM ·Business Wire

United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the remainder of its previously announced $2 billion share repurchase authorization. To

Sep 8, 2026, 7:00 AM ·Business Wire

United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis

Nebulized Tyvaso® (treprostinil) Inhalation Solution will be the first and only inhaled anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF) if approved by the U.S. Food and Drug Administration

Sep 2, 2026, 7:00 AM ·Business Wire

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

United Therapeutics Corporation (Nasdaq: UTHR) announced today that company executives will provide overviews and updates during fireside chat sessions at four upcoming investor conferences. Martine Rothblatt,

Sep 1, 2026, 7:00 AM ·Business Wire

United Therapeutics Corporation UTHR · News